8-KEarnings & ResultsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 12, 2026)

Filed January 12, 2026For Securities:DXCM

Summary

This 8-K filing from DexCom, Inc. (DXCM) serves as a notification regarding upcoming presentations and releases of preliminary financial results. President and CEO Jake Leach is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, where he will share unaudited financial results for the fourth quarter and full fiscal year 2025, along with initial financial outlook for fiscal year 2026. Investors should note that these results are preliminary and subject to finalization in the upcoming Form 10-K. The filing also references a business update press release issued on January 7, 2026, and includes these materials as exhibits. It's crucial for investors to understand that forward-looking statements within these releases are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

Key Highlights

  • 1DexCom to report preliminary unaudited Q4 and full-year 2025 financial results on January 12, 2026.
  • 2Company will provide initial financial outlook for fiscal year 2026.
  • 3Information to be presented at the J.P. Morgan 44th Annual Healthcare Conference.
  • 4Preliminary results are subject to finalization in the upcoming Form 10-K.
  • 5Filing includes two exhibits: a press release dated January 12, 2026, and a business update dated January 7, 2026.
  • 6Forward-looking statements are included, carrying inherent risks and uncertainties.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce that DexCom will be presenting preliminary, unaudited financial results for Q4 and FY2025, and providing its initial financial outlook for FY2026 at the J.P. Morgan Healthcare Conference on January 12, 2026. It also serves as a notification of attached press releases containing this information.

No, the financial results mentioned in this filing are preliminary and unaudited. They are subject to finalization as part of DexCom's preparation of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

DexCom will provide its initial financial outlook for fiscal year 2026. This will include guidance on key metrics such as total revenue, Non-GAAP Gross Profit Margin, and Non-GAAP Operating Margin, along with expected growth rates.

Investors should refer to DexCom's upcoming Form 10-K filing for the finalized financial results for fiscal year 2025. Additionally, any forward-looking statements made in presentations or press releases are subject to risks and uncertainties detailed in DexCom's most recent periodic reports (Form 10-K and 10-Q) and subsequent filings.